Executive Summary
Overnight filings reveal a bifurcated market environment where industrial and commodity-linked companies are delivering robust growth, while several healthcare and tech names face headwinds. Palantir Technologies reported staggering 92.8% YoY revenue growth and raised guidance, while ADM's adjusted EPS surged 98% YoY, leading to upward revisions in full-year forecasts.
Conversely, Ingredion and Smith & Nephew both cut guidance due to operational disruptions and product headwinds, respectively. Insider activity was mixed: a coordinated insider buying spree at SPAC East West Ave Acquisition Corp. contrasts with significant stock sales at Snowflake and New Oriental Education. Capital allocation trends show a strong preference for share repurchases, with DuPont, Grab, and Equinor announcing or executing buybacks. A notable pattern is the divergence between GAAP and adjusted earnings, with companies like Qnity Electronics and Eve Holding showing improved operational metrics but wider GAAP losses due to non-recurring items.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Form 4 · Schedule 13D · 10-Q · 8-K
Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from August 03, 2026.
Investment Signals (11)
- Palantir Technologies ↓ (BULLISH)▲
Q2 revenue surged 92.8% YoY to $1.935B, net income up 225% YoY, and gross margins expanded to 84.7%. The company is a clear leader in AI-driven analytics with accelerating growth.
- Archer-Daniels-Midland Co ↓ (BULLISH)▲
Adjusted EPS of $1.84 nearly doubled YoY (+98%), with total segment operating profit up 75%. Full-year guidance was raised sharply to $5.15-$5.60, driven by a constructive biofuels environment.
- Grab Holdings ↓ (BULLISH)▲
Record Q2 results, a new $750M share repurchase program, and raised full-year guidance signal strong operational momentum and management confidence in Southeast Asia's leading superapp.
- DuPont de Nemours ↓ (BULLISH)▲
Q2 net sales up 4% YoY (4% organic), exceeding guidance. Operating EBITDA rose 6%, and the company announced a $250M Q3 buyback, indicating confidence despite margin pressure in one segment.
- East West Ave Acquisition Corp. ↓ (BULLISH)▲
CEO Huang Maoli bought 100,000 shares, CFO Kerkaert Thomas John bought 40,000, and two directors bought 30,000 combined. This coordinated insider buying at a SPAC is a strong signal of conviction in a pending deal.
- Snowflake Inc. ↓ (BEARISH)▲
EVP of Product Management sold 20,000 shares for ~$6M under a 10b5-1 plan. While pre-planned, the large sale at $300/share may cap near-term upside sentiment.
- ▲
Director Zhuge Yue sold 1,200 ADS for ~$71.3K across four transactions. While not a massive sale, insider selling at a Chinese ADR adds to regulatory overhang concerns.
- Smith & Nephew ↓ (BEARISH)▲
Full-year revenue guidance cut from ~6% to ~4% growth due to a headwind from skin substitutes. This guidance revision signals a material operational challenge in a key product line.
- Ingredion Inc ↓ (BEARISH)▲
Adjusted EPS fell 2% YoY and adjusted operating income dropped 5%. Full-year guidance was revised down to mid-single-digit decline, with the Argo plant disruption and acquisition costs weighing on performance.
-
While adjusted EBITDA rose 24% YoY, GAAP net income fell 31% and GAAP EPS dropped 34%. The large gap between adjusted and GAAP earnings warrants scrutiny of non-recurring charges. [MIXED/BEARISH]
-
CEO Stephen Hood was awarded 100,000 shares, and the entire board and management received stock awards. This is a classic alignment move, but the lack of any cash purchase suggests the company is using equity to retain talent. [NEUTRAL/BULLISH]
Risk Flags (9)
- Ingredion/Operational Disruption↓ [HIGH RISK]▼
Food & Industrial Ingredients–U.S./CAN operating income plunged 33% YoY due to Argo plant disruptions. Net financing costs surged to $55M from $12M due to FX hedges on the Tate & Lyle acquisition.
- Lipocine/Clinical Failure↓ [HIGH RISK]▼
LPCN 1154 for postpartum depression failed its Phase 3 primary endpoint. While a post-hoc analysis showed some efficacy, the company acknowledges data validity questions, creating binary risk around the upcoming FDA meeting.
- Eve Holding/Cash Burn↓ [HIGH RISK]▼
Operating cash flow worsened to a use of $115.3M in H1 2026 from $80.5M. Total equity collapsed from $123.8M to just $22.8M, and the company raised $178.3M in new debt, increasing financial leverage.
- Gartner/Revenue Decline↓ [MEDIUM RISK]▼
Total revenues declined slightly YoY to $1.676B, driven by a sharp 8.8% drop in Consulting. The elimination of the 'Other' revenue line indicates a divestiture, and interest expense surged 88.7% YoY.
- IDEAYA Biosciences/Deepening Losses↓ [MEDIUM RISK]▼
Net loss widened to $112.5M in Q2 from $98.5M in Q1, driven by increased R&D and G&A. While cash runway is long, the company is considering reducing investment in a key trial (OptimUM-09) to conserve capital.
- Company 0000083246/Net Interest Income Decline↓ [MEDIUM RISK]▼
Total interest income fell 9% YoY in Q2 and 10% in H1, driven by lower loan and short-term investment income. This is a classic sign of a bank facing margin compression in a falling rate environment.
- Toyota Motor Corp/Operating Income Decline↓ [MEDIUM RISK]▼
Despite a 75.6% surge in net income, operating income declined 8.8% YoY. The full-year forecast projects further declines of 9.7% and 15.5% for operating income and net income, respectively.
- Pyrophyte Acquisition Corp/SPAC Time Decay↓ [MEDIUM RISK]▼
The sponsor is depositing $100K/month to extend the deadline to April 2027, but no business combination has been announced. This is a pre-revenue SPAC with increasing time pressure to find a deal.
- Sequans Communications/No Data Disclosed↓ [LOW RISK]▼
The filing contains no specific financial figures, making it impossible to assess performance. This lack of transparency is a red flag for a company that may be struggling.
Opportunities (9)
- Palantir Technologies/AI Dominance↓ (OPPORTUNITY)◆
With Q2 revenue growth of 92.8% YoY and net income up 225%, Palantir is a pure-play AI winner. The 84.7% gross margin and accelerating growth make it a core holding for AI exposure.
- Archer-Daniels-Midland Co/Biofuels Tailwind↓ (OPPORTUNITY)◆
Adjusted EPS nearly doubled YoY, and guidance was raised sharply. The constructive biofuels environment and record meal exports from Brazil provide a strong macro tailwind for the ag giant.
- DuPont de Nemours/Spin-off Value↓ (OPPORTUNITY)◆
Q2 results exceeded guidance, and the company announced a $250M buyback. The potential separation of its businesses could unlock significant shareholder value, as seen in the Diversified Industrials margin expansion.
- IDEAYA Biosciences/Registrational Catalyst↓ (OPPORTUNITY)◆
The OptimUM-02 trial met its primary endpoint with a 58% reduction in the risk of progression (HR: 0.42). An NDA filing under RTOR is expected H2 2026, which could be a major catalyst for the stock.
- Grab Holdings/Record Results + Buyback↓ (OPPORTUNITY)◆
Record Q2 results combined with a new $750M buyback and raised guidance make Grab a compelling growth story in Southeast Asia. The buyback signals management's view that the stock is undervalued.
- East West Ave Acquisition Corp./Insider Conviction↓ (OPPORTUNITY)◆
The CEO, CFO, and directors collectively bought 170,000 shares. This level of insider buying at a SPAC is rare and suggests a high-conviction deal is imminent.
- Quanta Services/Infrastructure Play↓ (OPPORTUNITY)◆
The $2.0B senior notes offering at attractive rates (4.85%-5.55%) will be used to repay commercial paper and fund general corporate purposes. This positions Quanta to capitalize on the growing electrical infrastructure buildout.
- Danaos Corp/Stable Cash Flows↓ (OPPORTUNITY)◆
The company re-elected directors and ratified auditors, signaling stability. The container shipping sector is cyclical, but Danaos's strong balance sheet and cash flows offer a defensive play in the space.
- Bitzero Holdings/Collaboration Catalyst↓ (OPPORTUNITY)◆
The collaboration with Vertiv to deepen technical and supply chain capabilities could be a precursor to a major data center or Bitcoin mining expansion. No financials were disclosed, but the partnership is a positive signal.
Sector Themes (6)
- AI & Tech Growth Divergence◆
Palantir's 92.8% revenue growth and 225% net income surge starkly contrast with Gartner's revenue decline and Snowflake insider selling. The market is rewarding AI-native companies while legacy tech firms struggle to adapt.
- Ag & Commodities Supercycle◆
ADM's 98% adjusted EPS growth and 75% segment profit surge, alongside Ingredion's mixed results, highlight a bifurcated ag sector. Companies with exposure to biofuels and global grain exports are outperforming those with operational disruptions.
- Healthcare Binary Risk◆
Lipocine's Phase 3 failure and IDEAYA's positive Phase 2 results underscore the binary nature of biotech investing. The upcoming FDA meeting for Lipocine and NDA filing for IDEAYA will be key catalysts.
- SPAC Insider Buying Signal◆
The coordinated insider buying at East West Ave Acquisition Corp. (CEO, CFO, directors, and 10% owner) is a rare and powerful signal. This contrasts with the time decay risk at Pyrophyte Acquisition Corp., which has yet to announce a deal.
- Share Buyback Wave◆
DuPont ($250M), Grab ($750M), Equinor (NOK 252M weekly), and BBVA (6.98M shares) all announced or executed buybacks. This trend suggests management teams across sectors see their stocks as undervalued and are returning capital to shareholders.
- GAAP vs. Adjusted Earnings Gap◆
Qnity Electronics and Eve Holding both show a widening gap between GAAP losses and adjusted profits. Investors should scrutinize non-recurring charges and stock-based compensation to assess true underlying performance.
Watch List (8)
-
Scheduled for Q3 2026. The outcome will determine the path forward for LPCN 1154 after its Phase 3 failure. A positive meeting could be a major catalyst; a negative one could be devastating.
-
The company is filing under RTOR with completion expected H2 2026. Approval for darovasertib in metastatic uveal melanoma would be a transformative event.
-
Shareholders approved the 595 pence all-cash offer. The closing of this deal and integration progress will be key to Ingredion's future growth profile.
-
The company cut guidance due to a $20M-$40M headwind. Watch for further updates on this product line and the impact of the additional $50M in efficiency savings.
-
With cash burn accelerating and equity collapsing, the company will likely need to raise additional capital. Watch for any equity or debt offerings in the coming quarters.
-
The coordinated insider buying suggests a deal announcement is imminent. Watch for a target and valuation disclosure.
-
The term loan credit agreement to finance the SEGRO acquisition is a major event. Watch for regulatory approvals and the finalization of the deal.
-
The forecast for declining operating and net income in FY2027 warrants monitoring. Any further guidance cuts would be a negative signal for the auto sector.
Filing Analyses
(50)
03-08-2026
Director Delta John was awarded 62,458 Class A Common Stock. Delta John holds 74,458 shares after the transaction.
- · Director Delta John was awarded 62,458 Class A Common Stock
03-08-2026
Director Jacobson Andrew P. was awarded 77,246 Class A Common Stock. Jacobson Andrew P. holds 77,246 shares after the transaction.
- · Director Jacobson Andrew P. was awarded 77,246 Class A Common Stock
03-08-2026
Chief Executive Officer HOOD STEPHEN was awarded 100,000 Class A Common Stock. HOOD STEPHEN holds 100,000 shares after the transaction.
- · Chief Executive Officer HOOD STEPHEN was awarded 100,000 Class A Common Stock
03-08-2026
Chief Financial Officer Hansen-Chambers Peter was awarded 12,500 Class A Common Stock. Hansen-Chambers Peter holds 25,000 shares after the transaction.
- · Chief Financial Officer Hansen-Chambers Peter was awarded 12,500 Class A Common Stock
- · Chief Financial Officer Hansen-Chambers Peter was awarded 12,500 Class A Common Stock
03-08-2026
Director Huang Guoquan was awarded 64,663 Class A Common Stock. Huang Guoquan holds 246,481 shares after the transaction.
- · Director Huang Guoquan was awarded 64,663 Class A Common Stock
03-08-2026
Chief Accounting Officer Beckley Stanley was awarded 25,000 Class A Common Stock. Beckley Stanley holds 25,000 shares after the transaction.
- · Chief Accounting Officer Beckley Stanley was awarded 25,000 Class A Common Stock
03-08-2026
Director SOHN YOUNG gifted 9 Common Stock. SOHN YOUNG holds 15,243 shares after the transaction.
- · Director SOHN YOUNG gifted 9 Common Stock
03-08-2026
Catalyst4, Inc., together with Robert Brown, Ekemini Riley, and Mark Vorsatz (collectively the Reporting Persons), filed an amended Schedule 13D/A with the SEC on August 3, 2026, disclosing a beneficial ownership of 20,906,689 shares of MapLight Therapeutics, Inc. (MPLT) common stock, representing a 47.9% stake. The filing reports the acquisition of an additional 1,209,225 shares in open-market purchases over three days in late July 2026 for an aggregate purchase price of approximately $15.3 million. While this represents a material increase in their ownership percentage, the filing notes that these additional purchases had already been disclosed on a Form 4 filed on July 30, 2026.
- · The additional 1,209,225 shares were acquired in the open market on July 28, 29, and 30, 2026 at prices ranging from $10.295 to $13.00 per share.
- · The earlier Schedule 13D was filed on November 20, 2025.
- · No borrowed funds or financing arrangements were used in the share purchases; source of funds was Catalyst's working capital.
- · The filing is an amendment (No. 1) to the initial Schedule 13D.
03-08-2026
Chief Strategy Officer Langlais Kerri M. exercised/converted 500,000 Common stock, $0.001 par value per share. Langlais Kerri M. holds 4,380,381 shares after the transaction.
- · Chief Strategy Officer Langlais Kerri M. exercised/converted 500,000 Common stock, $0.001 par value per share
- · Chief Strategy Officer Langlais Kerri M. disposed to the issuer 276,500 Common stock, $0.001 par value per share
- · Chief Strategy Officer Langlais Kerri M. exercised/converted 500,000 Restricted Stock Units
03-08-2026
Director Sunner Navtej Singh was awarded 69,567 Class A Common Stock. Sunner Navtej Singh holds 69,567 shares after the transaction.
- · Director Sunner Navtej Singh was awarded 69,567 Class A Common Stock
03-08-2026
Chief Financial Officer Fleury Patrick exercised/converted 500,000 Common stock, $0.001 par value per share. Fleury Patrick holds 500,000 shares after the transaction.
- · Chief Financial Officer Fleury Patrick exercised/converted 500,000 Common stock, $0.001 par value per share
- · Chief Financial Officer Fleury Patrick exercised/converted 500,000 Restricted Stock Units
03-08-2026
Director Verjee Irfan bought 10,000 Common Stock. Verjee Irfan holds 10,000 shares after the transaction.
- · Director Verjee Irfan bought 10,000 Common Stock
03-08-2026
Director Parikh Samir bought 20,000 Common Stock. Parikh Samir holds 20,000 shares after the transaction.
- · Director Parikh Samir bought 20,000 Common Stock
03-08-2026
Director Zhuge Yue sold 1,200 ADS at $59.41 (~$71.3K). 4 transactions reported in total. Zhuge Yue holds 1,200 shares after the transaction.
- · Director Zhuge Yue sold 170 ADS at $58.96 (~$10K)
- · Director Zhuge Yue sold 400 ADS at $59.00 (~$23.6K)
- · Director Zhuge Yue sold 400 ADS at $60.00 (~$24K)
- · Director Zhuge Yue sold 1,200 ADS at $59.41 (~$71.3K)
03-08-2026
EVP, Product Management Kleinerman Christian sold 20,000 Common Stock at $300.00 (~$6M). Kleinerman Christian holds 33,568 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · EVP, Product Management Kleinerman Christian sold 20,000 Common Stock at $300.00 (~$6M)
- · EVP, Product Management Kleinerman Christian sold 5,000 Common Stock at $300.00 (~$1.5M)
- · EVP, Product Management Kleinerman Christian sold 4,986 Common Stock at $300.00 (~$1.5M)
03-08-2026
CFO Kerkaert Thomas John bought 40,000 Common Stock. Kerkaert Thomas John holds 40,000 shares after the transaction.
- · CFO Kerkaert Thomas John bought 40,000 Common Stock
03-08-2026
CEO Huang Maoli bought 100,000 Common Stock. Huang Maoli holds 100,000 shares after the transaction.
- · CEO Huang Maoli bought 100,000 Common Stock
03-08-2026
10% owner East West Avenue LLC bought 192,500 Common Stock. East West Avenue LLC holds 2,507,500 shares after the transaction.
- · 10% owner East West Avenue LLC bought 192,500 Common Stock
- · 10% owner East West Avenue LLC bought 192,500 Private Rights
03-08-2026
Director BHUTANI ASHISH was awarded 1,728 Class A Common Stock. BHUTANI ASHISH holds 35,799 shares after the transaction.
- · Director BHUTANI ASHISH was awarded 1,728 Class A Common Stock
03-08-2026
Director Naughton Eileen was awarded 1,728 Class A Common Stock. Naughton Eileen holds 8,586 shares after the transaction.
- · Director Naughton Eileen was awarded 1,728 Class A Common Stock
03-08-2026
Director Olian Judy D. was awarded 1,728 Class A Common Stock. Olian Judy D. holds 31,462 shares after the transaction.
- · Director Olian Judy D. was awarded 1,728 Class A Common Stock
03-08-2026
Director Lynton Michael was awarded 1,728 Class A Common Stock. Lynton Michael holds 34,196 shares after the transaction.
- · Director Lynton Michael was awarded 1,728 Class A Common Stock
03-08-2026
Director Joubert Paul G. was awarded 1,728 Class A Common Stock. Joubert Paul G. holds 44,196 shares after the transaction.
- · Director Joubert Paul G. was awarded 1,728 Class A Common Stock
03-08-2026
Director BUSH ANTOINETTE COOK was awarded 1,728 Class A Common Stock. BUSH ANTOINETTE COOK holds 24,168 shares after the transaction.
- · Director BUSH ANTOINETTE COOK was awarded 1,728 Class A Common Stock
03-08-2026
Director He Eric exercised/converted 1,591 ADSs. He Eric holds 86,162 shares after the transaction.
- · Director He Eric exercised/converted 1,591 ADSs
- · Director He Eric exercised/converted 1,591 RSU (Restricted Stock Unit)
04-08-2026
Palantir Technologies reported a strong Q2 2026 with revenue of $1.935B, up 92.8% YoY from $1.004B, and net income attributable to common stockholders of $1.062B, up 225% from $0.327B. For the six-month period, revenue grew 89.0% to $3.568B and net income rose 257% to $1.932B. However, the company recorded an accumulated other comprehensive loss of $(7.1M) compared to a gain of $13.9M at year-end 2025, driven by foreign currency translation and unrealized losses on securities.
- · Earnings per share (diluted) for Q2 2026 was $0.41, up from $0.13 in Q2 2025.
- · Earnings per share (diluted) for H1 2026 was $0.75, up from $0.21 in H1 2025.
- · Gross profit for Q2 2026 was $1.639B (84.7% margin) vs $0.811B (80.8% margin) in Q2 2025.
- · Total operating expenses for Q2 2026 were $726.6M, up 34.2% from $541.4M in Q2 2025.
- · Stock-based compensation for H1 2026 was $466.8M, up 48.0% from $315.3M in H1 2025.
- · The company repurchased 8 shares of common stock for $1,500 during H1 2026.
- · Net unrealized loss on available-for-sale securities was $16.8M in H1 2026 vs $2.3M in H1 2025.
- · Foreign currency translation adjustments were a loss of $4.2M in H1 2026 vs a gain of $12.7M in H1 2025.
- · Total equity increased to $9.885B as of June 30, 2026 from $7.488B as of December 31, 2025.
- · Noncontrolling interests were $110.7M as of June 30, 2026 vs $100.7M as of December 31, 2025.
- · The company held $7.195B in U.S. Treasury securities as marketable securities as of June 30, 2026.
- · Publicly-traded equity securities increased to $184.1M as of June 30, 2026 from $23.4M as of December 31, 2025.
- · Accounts receivable increased 42.5% to $1.485B, indicating potential collection risk or strong sales growth.
- · Deferred revenue (current) grew 41.7% to $579.4M, while noncurrent deferred revenue declined 27.0% to $33.7M.
- · Customer deposits (current) increased 26.6% to $452.1M.
- · Net cash provided by operating activities was $2.115B in H1 2026, up 149% from $0.850B in H1 2025.
- · Net cash used in investing activities was $1.510B in H1 2026, down 24.8% from $2.007B in H1 2025.
- · Net cash provided by financing activities was $8.4M in H1 2026 vs net cash used of $22.4M in H1 2025.
- · The company's accumulated deficit improved by 54.2% to $1.630B from $3.562B at year-end 2025.
04-08-2026
Ingredion reported mixed Q2 2026 results: adjusted EPS of $2.82 (down 2% YoY from $2.87) and adjusted operating income of $258M (down 5% YoY), while reported EPS fell sharply to $1.78 from $2.99 due to impairment and acquisition costs. Texture & Healthful Solutions continued its volume growth streak (+5% operating income YoY), but Food & Industrial Ingredients–U.S./CAN operating income plunged 33% YoY due to Argo plant disruptions. The company reaffirmed full-year adjusted EPS guidance of $10.30–$10.90 and announced that Tate & Lyle shareholders approved its 595 pence all-cash offer, marking progress on the pending acquisition.
- · Net financing costs surged to $55M in Q2 2026 from $12M in Q2 2025, primarily due to a $47M mark-to-market FX loss on British pound sterling hedges related to the Tate & Lyle acquisition.
- · The reported effective tax rate increased to 33.7% from 23.6% a year ago, driven by the gain on sale of the Pakistan business and Mexican peso impacts.
- · Full-year 2026 adjusted operating income guidance was revised down to mid-single-digit decline (from prior expectations) due to the Pakistan sale.
- · Food & Industrial Ingredients–U.S./CAN operating income is now expected to be down 20-25% for full-year 2026, reflecting Argo plant headwinds.
- · All Other operating loss is now anticipated to be approximately $(15)M for full-year 2026, removing the second-half contribution from the Pakistan business.
- · Cash from operations guidance for full-year 2026 was narrowed to $700M–$800M.
- · Capital expenditures guidance for full-year 2026 is $450M–$490M.
- · Third quarter 2026 net sales expected up low single-digits, but reported and adjusted operating income both expected down mid-single-digits YoY.
04-08-2026
ZTO Express (Cayman) Inc. filed a Form 6-K with the SEC on August 4, 2026, attaching a monthly return on securities movements submitted to the Stock Exchange of Hong Kong. The filing is a routine regulatory disclosure and contains no financial results or material operational updates.
04-08-2026
Lipocine reported Q2 2026 net loss of $2.6 million (diluted EPS $(0.32)) compared to a net loss of $2.2 million (diluted EPS $(0.41)) in Q2 2025, reflecting a wider net loss while per-share loss improved due to a higher share count. Total revenues fell to $0.19 million from $0.62 million, as license revenue of $0.5 million in the prior-year period was not repeated. However, cash and marketable securities increased significantly to $23.3 million from $14.9 million at year-end 2025, notably from equity financing. LPCN 1154 for postpartum depression failed its Phase 3 primary endpoint, though a post-hoc exclusion of one high-enrolling site showed statistically significant improvement; a new Phase 3 trial has been initiated and an FDA guidance meeting is scheduled for Q3 2026.
- · LPCN 1154 failed its Phase 3 primary endpoint; a post-hoc analysis excluding one high-enrolling site showed efficacy, but the company acknowledges data validity questions.
- · FDA guidance meeting for LPCN 1154 scheduled for Q3 2026; a new placebo-controlled PPD trial has been initiated.
- · Pharmalink received marketing authorization for TESTYRA® (TLANDO) in the UAE on July 8, 2026.
- · Q2 2026 R&D expense was $2.0M vs $2.1M in Q2 2025 (down 4.8%), but H1 2026 R&D expense rose to $4.8M from $3.2M (up 50.3%) due to Phase 3 study costs and personnel.
- · G&A expense increased to $1.0M in Q2 2026 from $0.9M in Q2 2025 (up 11.3%), and to $2.2M from $2.0M in H1 (up 9.1%), due to higher consulting and professional fees.
- · Weighted average diluted shares outstanding increased to 8.22M in Q2 2026 from 5.35M in Q2 2025, reflecting equity financing.
- · Accumulated deficit grew to $(215.7M) as of June 30, 2026 from $(209.4M) at December 31, 2025.
04-08-2026
Grab Holdings Limited reported record financial results for Q2 2026, announced a $750 million share repurchase program, and raised its full-year guidance. The filing highlights strong operational performance and a commitment to returning capital to shareholders.
- · The filing is a Form 6-K for the month of August 2026.
- · The announcement was made on August 4, 2026 Singapore time.
- · The company raised its full-year guidance.
04-08-2026
DuPont reported Q2 2026 net sales of $1.819 billion, up 4% YoY (4% organic), exceeding guidance. GAAP income from continuing operations surged to $191 million from $24 million, while operating EBITDA rose 6% to $448 million. However, Healthcare & Water Technologies operating EBITDA margin contracted 30 bps to 30.1% due to unfavorable mix and growth investments, and Water Technologies saw weakness in the Middle East. The company raised full-year 2026 guidance and announced a $250 million share repurchase plan for Q3.
- · Healthcare & Water Technologies operating EBITDA margin declined 30 bps to 30.1% due to unfavorable mix and growth investments.
- · Water Technologies organic sales grew only low-single digits, with weakness in the Middle East.
- · Diversified Industrials operating EBITDA margin expanded 70 bps to 22.1% on favorable mix and productivity.
- · Full-year 2026 guidance raised: net sales $7.16B-$7.19B, operating EBITDA $1.75B-$1.77B, adjusted EPS $7.17-$7.32.
- · Company completed a 1-for-3 reverse stock split effective June 24, 2026.
- · Aramids divestiture closed April 1, 2026 for $1.2B cash, $300M note, and $325M equity interest.
- · Electronics business separation completed November 1, 2025, creating Qnity Electronics.
- · GICS code changed to Industrials effective July 31, 2026.
04-08-2026
Equinor ASA disclosed weekly buy-back transactions under the third tranche of its 2026 share buy-back programme, repurchasing 660,000 shares on the Oslo Stock Exchange (OSE) from July 27-31, 2026, for a total of NOK 252,276,085.00. The daily weighted average share price ranged from NOK 373.79 to NOK 388.34. Accumulated buy-backs under the tranche total 880,000 shares for NOK 338,403,385.00, with no activity on CEUX or TQEX venues during the period.
- · All buy-backs were executed on the Oslo Stock Exchange (OSE) with no transactions on CEUX or TQEX venues.
- · Daily share volumes ranged from 125,000 to 150,000 shares.
- · Previously disclosed buy-backs under the tranche were 220,000 shares at a weighted average price of NOK 391.4877.
04-08-2026
ING Groep N.V. filed a Form 6-K with the SEC on August 4, 2026, attaching a press release issued the same day. The filing is a routine foreign issuer report under Rule 13a-16, signed by Head of Media Relations Raymond Vermeulen. No specific financial results or material events are disclosed in the filing itself.
- · The filing is a Form 6-K for the month of August 2026.
- · Commission File Number: 001-14642.
- · The press release is attached as Exhibit 99.1 but its content is not included in the filing text.
04-08-2026
For the quarter ended June 30, 2026, net income rose 57% YoY to $390M, driven by a 5% increase in net interest income and an 18% rise in other revenues, while the provision for credit losses reversed to a benefit of $38M versus an expense of $42M a year ago. However, total interest income declined 9% YoY to $1,732M due to lower loan and short-term investment income, and total operating expenses edged up 1% to $703M. For the six-month period, net income grew 52% to $681M, but total interest income fell 10% to $3,428M and net cash used in operations was $2,733M versus $445M used in the prior period.
- · Interest income from loans fell 10% YoY to $801M in Q2 2026, and short-term investment income dropped 34% to $271M.
- · Interest expense on deposits declined 16% YoY to $771M, while total interest expense fell 15% to $1,183M.
- · Other fees and commissions grew 35% YoY to $241M, and trading revenue rose 11% to $212M.
- · Support services from HSBC affiliates increased 6% to $483M, while salaries and employee benefits decreased 12% to $141M.
- · Cash used in operating activities for H1 2026 was $2,733M, compared to $445M used in H1 2025, driven by a $3,375M net change in trading assets and liabilities.
- · Total assets grew 4.8% to $180,708M from December 31, 2025, driven by increases in trading assets and securities.
- · Common dividends declared in Q2 2026 were $300M, down 70% from $1,000M in Q2 2025.
- · Accumulated other comprehensive loss widened to $1,418M from $1,379M at year-end 2025, primarily due to unrealized losses on investment securities.
04-08-2026
Quanta Services, Inc. (NYSE: PWR) announced the pricing of a senior notes offering totaling $2.0 billion across three tranches: $500 million of 4.850% notes due 2029, $750 million of 5.300% notes due 2033, and $750 million of 5.550% notes due 2036. The offering is expected to close on August 6, 2026, with net proceeds used for general corporate purposes, including repayment of outstanding borrowings under its commercial paper program and senior credit facility. The notes are priced at slight discounts to par (99.950%, 99.757%, and 99.696% of face value, respectively).
- · The offering is made under an effective shelf registration statement on Form S-3 filed with the SEC on August 2, 2024.
- · Joint book-running managers vary by tranche: 2029 Notes (8 managers), 2033 Notes (8 managers), 2036 Notes (8 managers).
- · Proceeds will be used for general corporate purposes, including repayment of commercial paper program and senior credit facility borrowings.
04-08-2026
Gartner Inc. reported Q2 2026 net income of $275.5M, up 14.4% from $240.8M in Q2 2025, with diluted EPS rising to $4.14 from $3.11. Total revenues declined slightly to $1.676B from $1.686B, as growth in Insights (+2.1%) and Conferences (+15.5%) was offset by a sharp drop in Consulting (-8.8%) and the elimination of the 'Other' revenue line. The company generated $789.3M in operating cash flow in H1 2026, up from $697.1M, but spent $1.08B on share repurchases, contributing to a negative stockholders' equity of ($167.3M) at quarter-end.
- · The 'Other' revenue line, which contributed $55.9M in Q2 2025, was eliminated in Q2 2026, reflecting the divestiture of a non-core operation.
- · Gain from sale of divested operation was $739K in Q2 2026 and $5.4M for H1 2026.
- · Interest expense, net increased to $22.3M in Q2 2026 from $11.8M in Q2 2025, an 88.7% rise.
- · Total liabilities decreased to $7.361B from $7.765B at year-end 2025, primarily due to lower accounts payable and accrued liabilities.
- · The company's stockholders' equity turned negative to ($167.3M) from positive $319.9M at year-end 2025, driven by $1.08B in share repurchases.
- · Deferred revenues decreased to $2.756B from $2.810B at year-end 2025.
- · Fees receivable, net declined to $1.202B from $1.685B at year-end 2025, a 28.6% drop.
- · Cash used in financing activities was $1.073B in H1 2026 vs. $419.7M in H1 2025, mainly due to increased share repurchases.
04-08-2026
ADM reported strong Q2 2026 results with GAAP EPS of $1.87 (up from $0.45 in Q2 2025) and adjusted EPS of $1.84 (up 98% YoY). Total segment operating profit surged 75% YoY to $1.45 billion, driven by broad-based growth across all three segments—Ag Services & Oilseeds (+129%), Carbohydrate Solutions (+22%), and Nutrition (+51%). The company raised its full-year 2026 adjusted EPS guidance to $5.15–$5.60 (from $4.15–$4.70), citing a constructive biofuels environment and momentum in Nutrition. However, the Refined Products & Other subsegment declined 3% YoY, and equity earnings from Wilmar fell 22% YoY.
- · Global oilseed volumes increased approximately 5% YoY in Q2 2026.
- · Ag Services subsegment operating profit rose 159% YoY, driven by leveraging ADM's global asset network and the Barcarena, Brazil grain export terminal returning to full operations.
- · Crushing subsegment operating profit increased by $330 million YoY, with record meal exports from Brazil and the U.S.
- · Starches and Sweeteners subsegment operating profit rose only 7% YoY, as higher ethanol margins were partially offset by lower liquid sweetener volumes and margins in North America.
- · Vantage Corn Processors subsegment operating profit increased by $52 million YoY.
- · Human Nutrition subsegment operating profit rose 51% YoY, driven by Flavors growth and progress at the Decatur East plant.
- · Animal Nutrition subsegment operating profit rose 50% YoY due to operational improvements and portfolio actions.
- · Corporate results improved due to non-recurrence of prior-year impairment losses and lower financing costs, partially offset by higher performance-based compensation.
- · Other Business contribution decreased due to lower captive insurance results.
- · The company raised full-year 2026 adjusted EPS guidance to $5.15–$5.60 from $4.15–$4.70.
- · Capital expenditures projected at $1.3B to $1.5B.
04-08-2026
Lipocine Inc. reported a net loss of $2.62M for Q2 2026, wider than the $2.21M loss in Q2 2025, driven by a 69% drop in total revenue to $0.19M due to the absence of license revenue. While royalty revenue grew 55% to $0.19M, operating expenses remained flat at $3.03M, and the company raised $13.47M net through an ATM offering, boosting cash reserves. However, cash used in operations increased to $5.29M for the first half of 2026, and the accumulated deficit grew to $215.69M.
- · Cash and cash equivalents decreased to $4.98M at June 30, 2026 from $5.21M at December 31, 2025.
- · The company had $18.29M in government treasury bills at fair value at June 30, 2026.
- · Stock-based compensation expense was $123,543 for H1 2026, down from $136,207 in H1 2025.
- · The company sold 2,083,276 shares through its ATM offering in H1 2026, raising $13.47M net.
- · Accumulated deficit increased to $215.69M at June 30, 2026 from $209.40M at December 31, 2025.
04-08-2026
Bitzero Holdings Inc. filed a Form 6-K on August 4, 2026, announcing a collaboration with Vertiv to deepen its technical and supply chain capabilities. The filing includes a news release dated the same day but provides no financial figures or performance metrics.
- · The collaboration is focused on deepening technical and supply chain capabilities.
- · No financial details, revenue, or operational metrics were disclosed in the filing.
04-08-2026
Eve Holding, Inc. filed an 8-K on August 4, 2026, reporting its financial results for the second quarter of 2026 under Item 2.02. The filing includes financial statements and exhibits under Item 9.01. However, the filing does not disclose any specific financial metrics, revenue figures, earnings data, or period-over-period comparisons. Without quantitative data, the filing is purely informational and provides no basis for directional investment action.
- · Filing date: August 4, 2026
- · SEC filing size: 20 MB
- · AccNo: 0001554855-26-001687
- · Sector: not specified
- · No specific financial metrics, revenue, earnings, or guidance disclosed in the extracted summary
04-08-2026
Toyota Motor Corporation reported Q1 FY2027 results with sales revenues of ¥13,525.4 billion (+10.4% YoY) and net income attributable to Toyota Motor Corporation of ¥1,477.0 billion (+75.6% YoY). However, operating income declined 8.8% YoY to ¥1,063.4 billion, and the full-year forecast for operating income and net income both project declines of 9.7% and 15.5% respectively, indicating mixed performance.
- · Earnings per share (basic) for FY2027 Q1 was ¥120.69, up from ¥64.56 in FY2026 Q1.
- · Full-year FY2027 forecast EPS (basic) is ¥272.17.
- · Annual cash dividend per common share forecast for FY2027 is ¥100.00 (¥50.00 interim, ¥50.00 year-end), up from ¥95.00 in FY2026.
- · Total assets decreased to ¥102,635,116 million from ¥105,522,331 million at FY2026 year-end.
- · Total shareholders' equity decreased to ¥38,228,932 million from ¥41,020,068 million at FY2026 year-end.
- · Toyota Motor Corporation shareholders' equity ratio declined to 36.4% from 37.8% at FY2026 year-end.
04-08-2026
Pyrophyte Acquisition Corp. disclosed that its sponsor, Pyrophyte Acquisition LLC, deposited monthly extension amounts of $100,000 each into the company's trust account on June 8, 2026 and July 20, 2026. These deposits support a one-year extension of the deadline to consummate an initial business combination, moving the deadline from April 29, 2026 to April 29, 2027. The company remains a pre-revenue SPAC, with no business combination announced yet.
- · Shareholders approved the extension at an extraordinary general meeting on April 28, 2026.
- · The original deadline was April 29, 2026; extended to April 29, 2027.
- · The sponsor will deposit $100,000 per month during the extension period.
- · Two deposits have been made so far (June and July 2026).
04-08-2026
Danaos Corporation filed its Form 6-K for August 2026, reporting the results of its Annual General Meeting held on July 31, 2026, and including unaudited condensed consolidated financial statements for the three and six months ended June 30, 2026. At the AGM, Iraklis Prokopakis was re-elected as a Class II director, Petros Christodoulou resigned as a Class I director and was elected as a Class II director, and Deloitte was ratified as independent auditors. The filing also includes amended management, commercial agency, and restrictive covenant agreements.
- · The AGM was held on July 31, 2026.
- · Mr. Iraklis Prokopakis was re-elected as a Class II director for a three-year term expiring at the 2029 annual meeting.
- · Mr. Petros Christodoulou resigned as a Class I director and was elected as a Class II director for a three-year term expiring at the 2029 annual meeting.
- · Stockholders ratified the appointment of Deloitte Certified Public Accountants, S.A. as independent auditors.
- · The filing includes an amended and restated Management Agreement between Danaos Corporation and Danaos Shipping Company Limited, dated July 31, 2026.
- · The filing includes an amended and restated Commercial Agency Agreement between Danaos Corporation and Danaos Chartering Services Inc., dated July 31, 2026.
- · The filing includes an amended and restated Restrictive Covenant Agreement between Danaos Corporation, Dr. John Coustas, and Danaos Investment Limited, as Trustee of the 883 Trust, dated July 31, 2026.
04-08-2026
Qnity Electronics reported strong Q2 2026 results with net sales up 22% YoY to $1.4B and Adjusted Operating EBITDA up 24% to $431M. However, GAAP net income fell 31% to $136M and GAAP EPS dropped 34% to $0.59, while Adjusted EPS rose 53% to $1.19. The company raised full-year 2026 guidance on continued momentum.
- · Semiconductor Technologies segment sales grew 15.5% YoY to $744M.
- · Interconnect Solutions segment sales grew 30.2% YoY to $685M.
- · Adjusted Gross Profit was $666M in Q2 2026 vs $542M in Q2 2025 (pro forma), up 22.9%.
- · Full-year 2026 Adjusted EPS guidance raised to $4.40 - $4.60.
- · Full-year 2026 Adjusted Free Cash Flow guidance raised to $600M - $700M.
- · The company noted its ninth consecutive quarter of profitable growth.
- · GAAP net income declined 31% YoY despite strong revenue growth, indicating higher non-operating costs or significant items.
04-08-2026
Smith & Nephew reported H1 2026 revenue of $3,097M (+4.6% reported, +2.3% underlying) and Q2 revenue of $1,597M (+2.8% reported, +1.6% underlying). While trading profit margin improved to 18.3% and EPSA grew 11.0%, the company cut its full-year revenue growth guidance from ~6% to ~4% due to a headwind from skin substitutes (expected toward the upper end of the $20M-$40M range). Free cash flow declined 5.2% to $231M in H1, and the ENT segment saw a slight underlying decline of 1.6%.
- · Full-year revenue guidance reduced from ~6% to ~4% growth.
- · Headwind from skin substitutes expected toward the upper end of the previously guided $20M to $40M range.
- · Additional $50M in efficiency savings identified for 2026, bringing total to ~$200M.
- · Adjusted net debt/EBITDA leverage ratio at H1 2026 was 1.8x.
- · Underlying revenue growth on an average daily sales (ADS) basis was 3.1% for H1.
- · ENT segment underlying revenue declined 1.6% in H1.
04-08-2026
Eve Holding, Inc. reported a net loss of $34.2M for Q2 2026, significantly improved from a $64.7M loss in Q2 2025, driven by a 36.6% reduction in R&D expenses and a $2.3M gain from warrant liability remeasurement. However, operating cash flow worsened to a use of $115.3M in H1 2026 from $80.5M in H1 2025, and total equity collapsed from $123.8M at year-end 2025 to just $22.8M as accumulated deficit reached $810.1M. The company raised $178.3M in new debt during H1 2026, increasing long-term debt to $303.1M, while cash and investments fell to $394.7M from $384.1M.
- · Financial investments increased to $342.5M as of June 30, 2026 from $280.8M at December 31, 2025.
- · Warrant liability decreased to $1.7M from $4.6M, generating a $2.3M gain in Q2 2026.
- · Interest expense rose to $5.2M in Q2 2026 from $2.4M in Q2 2025, reflecting higher debt levels.
- · Capitalized software, net increased to $7.4M from $4.8M.
- · Property, plant & equipment, net grew to $13.6M from $10.6M, driven by tooling and construction in process.
- · Related party payables (current) remained high at $70.4M, essentially unchanged from year-end.
- · Cash paid for interest in H1 2026 was $6.0M, up from $4.3M in H1 2025.
04-08-2026
BBVA reported daily share repurchases of its BBVA.MC stock on the Madrid exchange (XMAD) from July 27 to August 3, 2026, totaling 6,980,298 shares at weighted average prices ranging from €22.8564 to €24.5812. The repurchases are part of a buyback program, with no activity on other venues. The weighted average price increased over the period, indicating a rising share price, but the daily repurchase volume fluctuated.
- · All repurchases were executed on the Madrid stock exchange (XMAD); no shares were bought on AQEU, CEUX, or TQEX.
- · Daily repurchase volumes varied: 1,050,000 (Jul 27), 1,100,000 (Jul 28), 1,350,000 (Jul 29), 1,040,000 (Jul 30), 1,175,000 (Jul 31), 1,265,298 (Aug 3).
- · Weighted average price per share ranged from €22.8564 (Jul 29) to €24.5812 (Aug 3), showing an overall upward trend.
04-08-2026
Sequans Communications reported unaudited financial results for Q2 2026, ended June 30, 2026. The filing is a routine earnings disclosure by the foreign private issuer, containing no qualitative commentary on performance trends. Without specific financial figures in the provided text, no balanced assessment of improvements or declines is possible.
04-08-2026
IDEAYA Biosciences reported Q2 2026 financial results with a net loss of $112.5M, wider than the $98.5M loss in Q1 2026, driven by increased R&D and G&A expenses. The company highlighted positive topline results from the registrational OptimUM-02 trial in metastatic uveal melanoma (mUM), which met its primary endpoint with a statistically significant improvement in median PFS (6.9 months vs. 3.1 months, HR: 0.42). However, overall survival data remains immature, and the company is assessing capital allocation, including potentially reducing investment in the neoadjuvant OptimUM-09 trial. Cash, cash equivalents, and marketable securities stood at ~$1.24B as of June 30, 2026, up from $972.9M at March 31, 2026, primarily due to a $323.4M public offering, with cash runway into 2030 unchanged.
- · OptimUM-02 trial met primary endpoint: median PFS 6.9 months (darovasertib combo) vs 3.1 months (ICT) by BICR (HR: 0.42; p<0.0001).
- · OS data immature; pre-specified interim OS analysis expected mid-2027.
- · NDA filing underway under RTOR with completion expected H2 2026.
- · IDEAYA assessing capital allocation; may reduce investment in OptimUM-09 neoadjuvant trial to focus on DLL3 and MTAP/KRAS programs.
- · IDE892 monotherapy expansion initiated in MTAP-deleted NSCLC and PDAC; MTD not yet reached.
- · IDE892 + IDE397 combination cohort initiated; expansion planned by year-end 2026 or early 2027.
- · IDE892 + RG6505 (Roche) Phase 1 combination trial targeting H2 2026 start in MTAP-deleted, RAS-mutant PDAC.
- · IDE849 global Phase 1/2 data expected H2 2026; FDA discussions ongoing for Phase 3 registrational trial design.
- · Hengrui targeting Phase 3 registrational trial for IDE849 in refractory SCLC in China by end of 2026.
- · IDE034 Phase 1 dose escalation data expected by end of 2026 or early 2027.
- · IDE574 Phase 1 dose escalation underway in solid tumors.
- · R&D Day on MTAP/CDKN2A, KRAS, and pancreatic cancer planned for Q4 2026.
- · Cash runway into 2030 unchanged despite increased net loss.
04-08-2026
Prologis, L.P. entered into a term loan credit agreement dated August 4, 2026, to finance its acquisition of SEGRO plc. The facility is led by JPMorgan Chase Bank, N.A. as administrative agent and sole lead arranger. The agreement includes financial covenants and pricing grids tied to credit ratings, with interest rates ranging from 0.675% to 1.55% per annum.
- · The credit agreement includes a 'Certain Funds Period' and provisions for extension of maturity date.
- · The facility is intended to finance the acquisition of at least a simple majority of SEGRO's outstanding shares.
- · The agreement includes guaranties from Prologis and certain affiliates.
- · The pricing grid includes an undrawn fee ranging from 0.10% to 0.30% per annum.
Get daily alerts with 11 investment signals, 9 risk alerts, 9 opportunities and full AI analysis of all 50 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Pre-Market SEC Filings Roundup
🇺🇸 More from United States
View all →August 03, 2026
US SEC Filings Daily Market Digest — August 03, 2026
US SEC Filings Daily Market Digest
August 03, 2026
US Activist Hedge Fund Institutional SEC 13D 13G — August 03, 2026
US Activist Hedge Fund Institutional SEC 13D 13G
August 03, 2026
S&P 500 Financials Sector SEC Filings — August 03, 2026
S&P 500 Financials Sector SEC Filings
August 03, 2026
S&P 500 Consumer Staples Sector SEC Filings — August 03, 2026
S&P 500 Consumer Staples Sector SEC Filings